Date: 2012-12-03
Type of information: R&D agreement
Compound: Transcend technology
Company: UCB (Belgium) biOasis Technologies (Canada)
Therapeutic area: CNS diseases
Type agreement: R&D
collaboration
Action mechanism: Transcend is a proven humanized protein (melanotransferrin) based Vector that transports both large and small compounds across the blood-brain barrier using validated process know as Receptor Mediated Transcytosis.
Disease:
Details: biOasis Technologies has entered into a research collaboration agreement with UCB to evaluate biOasis's Transcend technology in the area of the delivery of therapeutic compounds to the brain. In connection with this agreement, biOasis will conduct certain experiments to provide UCB with confirmation of the Transcend technology as it relates to the delivery of therapeutic compounds owned by UCB to the CNS.
Financial terms: Financial terms were not disclosed.
Latest news:
